 SHANGHAI and GAITHERSBURG, Md., Aug. 11, 2021 PRNewswire -- I-Mab the Company Nasdaq: IMAB, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced positive interim data from its U.S. phase 23 study NCT04341116 of plonmarlimab also known as TJM2 or TJ003234 for the treatment of cytokine release syndrome CRS in patients with severe COVID-19. 